Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo

Circulation

Volumn 94, Issue 10, 1996, Pages 2614-2619

  Chou, Tony M ^a   Sudhir, Krishnankutty ^a   Hutchison, Stuart J ^a   Ko, Eitetsu ^a   Amidon, Thomas M ^b   Collins, Peter ^c   Chatterjee, Kanu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Overlake Internal Medicine   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

arteries; endothelium; testosterone; vasculature

Indexed keywords

ADENOSINE TRIPHOSPHATE; ESTROGEN RECEPTOR; FULVESTRANT; GLIBENCLAMIDE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; POTASSIUM CHANNEL; PROSTAGLANDIN; TESTOSTERONE;

ANIMAL EXPERIMENT; ARTERY DIAMETER; ARTICLE; BLOOD FLOW VELOCITY; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DOG; DOPPLER ECHOGRAPHY; DOSE RESPONSE; FEMALE; INTRACORONARY INFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESISTANCE BLOOD VESSEL; VASODILATATION;

EID: 0029807020     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.10.2614     Document Type: Article

References (51)

1. Collins J. Prevalence of selected chronic conditions, United States 1986-88. Vital and Heath Statistics. Hyattsville, Md: Department of Health and Human Services, Centers for Disease Control, National Center for Health Statistics; 1993.
2. Gordon T, Kannel WB. Premature mortality from coronary heart disease: the Framingham study. JAMA. 1971;215:1617-1625.
3. Morbidity and Mortality Chartbook on Cardiovascular, Lung and Blood Diseases. Bethesda, Md: National Heart, Lung, and Blood Institute: 1992.
4. Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease: the Framingham Study. Ann Intern Med. 1978;89:157-161.
5. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325:756-762. See comments.
6. Henderson BE, Ross RK, Paganini HA, Mack TM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol. 1986;154:1181-1186.
7. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247-256.
8. Wren BG. The effect of oestrogen on the female cardiovascular system. Med J Aust. 1992;156:204-208.
9. Phillips GB. Relationship of serum sex hormones to coronary heart disease. Steroids. 1993;58:286-290. Discussion, 291-292.
10. Jiang CW, Sarrel PM, Lindsay DC, Poole WP, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17 betaoestradiol in vitro. Br J Pharmacol. 1991;104:1033-1037.
11. Sudhir K, Chou TM, Mullen WL, Hausmann D, Collins P, Yock PG, Chatterjee K, Mechanisms of estrogen-induced vasodilation in canine coronary conductance and resistance arteries. J Am Coll Cardiol. 1995;26:807-814.
12. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 1994;89:52-60.
13. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992;20:452-457.
14. Gisclard V, Miller VM, Vanhoutte PM. Effect of 17 beta-estradiol on endothelium-dependent responses in the rabbit. J Pharmacol Exp Ther. 1988;244:19-22.
15. Sigler LH, Tulgan J. Treatment of angina pectoris by testosterone propionate. N Y State J Med. 1943;43:1424-1428.
16. Walker TC. The use of testosterone propionate and estrogenic substance in the treatment of essential hypertension, angina pectoris and peripheral vascular disease. J Clin Endocrinol. 1942;2:560-568.
17. Hamm L. Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol. 1942;2:325-328.
18. Lesser MA. Testosterone propionate therapy in one hundred cases of angina pectoris. J Clin Endocrinol. 1946;6:549-557.
19. Rosano GM, Sarrel PM, Poole WP, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 1993;342:133-136. See comments.
20. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J. 1977;39:1217-1222.
21. Yue P, Chatterjee K, Beale C, Poole-Wilson PA, Collins P. Testosterone relaxes rabbit coronary arteries and aorta. Circulation. 1995; 91:1154-1160.
22. Chou TM, Sudhir K, Iwagana S, Chatterjee K, Yock PG. Measurement of volumetric coronary blood flow using simultaneous two-dimensional intravascular ultrasound and Doppler guidewire: validation in an animal model. Am Heart J. 1994;128:237-243.
23. Ludmer PL, Selwyn AP, Shook TL. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
24. Sudhir K, Mullen WL, Hausman D, Fitzgerald PJ, Chou TM, Yock PG, Chatterjee K. Contribution of endothelium-derived nitric-oxide to coronary arterial distensibility: an in vivo two-dimensional intravascular ultrasound study. Am Heart J. 1995;129:726-732.
25. Sudhir K, MacGregor JS, Amidon TM, Gupta M, Yock PG, Chatterjee K. Differential contribution of nitric oxide to regulation of vascular tone in coronary conductance and resistance arteries: intravascular ultrasound studies. Am Heart J. 1994;127:858-865.
26. Schnermann J, Schubert G, Hermle M, Herbst R, Stowe NT, Yarimizu S, Weber PC. The effect of inhibition of prostaglandin synthesis on tubuloglomerular feedback in the rat kidney. Pflugers Arch. 1979;379:269-279.
27. Miller WL, Lane GE, Carmichael SW, Bove AA. Indomethacin attenuates the constriction of canine epicardial coronary arteries to acetylcholine in the absence of endothelium: contribution of platelets to vasoconstriction in vivo. J Am Coll Cardiol. 1989;14:1794-1802.
28. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51:3867-3873.
29. Doucette JW, Corl D, Payne HM, Flynn AE, Goto M, Nassi M, Segal J. Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85:1899-1911.
30. Edwards E, Hamilton J, Duntley S. Testosterone propionate as a therapeutic agent in patients with organic disease of peripheral vessels. N Engl J Med. 1939;220:865-869.
31. Levine S, Likoff W. The therapeutic value of testosterone propionate in angina pectoris. N Engl J Med. 1943;228:770-772.
32. Bagatell CJ, Knopp RH, Vale WW, Rivier JE, Bremner WJ. Physiologic testosterone levels in normal men suppress high-density lipoprotein cholesterol levels. Ann Intern Med. 1992;116:967-973.
33. Schror K, Morinelli TA, Masuda A, Matsuda K, Mathur RS, Halushka PV. Testosterone treatment enhances thromboxane A2 mi metic induced coronary artery vasoconstriction in guinea pigs. Eur J Clin Invest. 1994;24(suppl 1):50-52.
34. Weyrich AS, Rejeski WJ, Brubaker PH, Parks JS. The effects of testosterone on lipids and eicosanoids in cynomolgus monkeys. Med Sci Sports Exerc. 1992;24:333-338.
35. Masuda A, Mathur R, Halushka PV. Testosterone increases thromboxane A2 receptors in cultured rat aortic smooth muscle cells. Circ Res. 1991;69:638-643.
36. McNutt RA, Ferenchick GS, Kirlin PC, Hamlin NJ. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. Am J Cardiol. 1988;62:164.
37. Mochizuki R, Richter K. Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use. Physician Sports Med. 1988;16:109-114.
38. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM, Rao DC. Evidence for an association between dehydroepiandroster-one sulfate and nonfatal, premature myocardial infarction in males. Circulation. 1994;89:89-93.
39. Phillips GB, Pinkernell BH, Jing TY. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb. 1994;14:701-706.
40. Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
41. Evans RM. The steroid and thyroid hormone receptor superfamily. Science. 1988;240:889-895.
42. McEwen BS. Non-genomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci. 1991;12:141-147.
43. Pietras RJ, Szego CM. Endometrial cell calcium and oestrogen action. Nature. 1975;253:357-359.
44. Dufy B, Vincent JD, Fleury H, Du PP, Gourdji D, Tixier VA. Membrane effects of thyrotropin-releasing hormone and estrogen shown by intracellular recording from pituitary cells. Science. 1979; 204:509-511.
45. Kelly MJ, Moss RL, Dudley CA, Fawcett CP. The specificity of the response of preoptic-septal area neurons to estrogen: 17alpha-estradiol versus 17beta-estradiol and the response of extrahypothalamic neurons. Exp Brain Res. 1977;30:43-52.
46. Christ M, Eisen C, Aktas J, Theisen K, Wehling M. The inositol-1,4,5-trisphosphate system is involved in rapid effects of aldosterone in human mononuclear leukocytes. J Clin Endocrinol Metab. 1993; 77:1452-1457.
47. Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am J Physiol. 1992;263:E974-E979.
48. Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz JL. A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology. 1992;131:1305-1312.
49. Wehling M, Christ M, Gerzer R. Aldosterone-specific membrane receptors and related rapid, non-genomic effects. Trends Pharmacol Sci. 1993;14:1-4.
50. Cantrill JA, Dewis P, Large DM, Newman M, Anderson DC. Which testosterone replacement therapy? Clin Endocrinol. 1984;21:97-107.
51. Inoue T, Tomoike H, Hisano K, Nakamura M. Endothelium determines flow-dependent dilation of the epicardial coronary artery in dogs. J Am Coll Cardiol. 1988;11:187-191.